U.S. FDA grants orphan drug designation to AmideBio’s glucagon analog for the treatment of congenital hyperinsulinism
- Thursday, April 23, 2020, 7:05
- Finance
- Add a comment
BOULDER, Colo., April 23, 2020 /PRNewswire/ — AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the…
About the Author
adminasapcorp has written 41546 stories on this site.